These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 18038486)

  • 21. The regulatory process: impacting the NP's role.
    Wysocki S
    Nurse Pract Forum; 1992 Jun; 3(2):56-7. PubMed ID: 1392671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classification of three steroids as schedule III anabolic steroids under the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2009 Dec; 74(232):63603-10. PubMed ID: 20169675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exemption of chemical mixtures. Final rule.
    Drug Enforcement Administration (DEA), U.S. Department of Justice
    Fed Regist; 2007 Mar; 72(47):10925-8. PubMed ID: 17450656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Aug; 67(154):51987-52007. PubMed ID: 12194173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designation of oripavine as a basic class of controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2007 Sep; 72(184):54208-10. PubMed ID: 17912784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Schedules of controlled substances; exempt anabolic steroid products. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Mar; 73(52):14178-9. PubMed ID: 18464343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Schedules of controlled substances: placement of ezogabine into Schedule V. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2011 Dec; 76(241):77895-99. PubMed ID: 22175093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schedules of controlled substances: rescheduling of the Food and Drug Administration approved product containing synthetic dronabinol [(-) - [DELTA] less than 9 greater than - (trans)-tetrahydrocannabinol] in sesame oil and encapsulated in soft gelatin capsules from schedule II to schedule III. Department of Justice (DOJ), Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1999 Jul; 64(127):35928-30. PubMed ID: 10558581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Sep; 69(188):58950-3. PubMed ID: 15455477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2010 Dec; 75(243):79296-300. PubMed ID: 21171485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exemption from import/export requirements for personal medical use. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Sep; 69(177):55343-7. PubMed ID: 15366181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schedule of controlled substances: placement of tramadol into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2014 Jul; 79(127):37623-30. PubMed ID: 25016619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exemption of chemical mixtures containing the List I chemicals ephedrine, N-methylephedrine, N-methylpseudoephedrine, norpseudoephedrine, phenylpropanolamine, and pseudoephedrine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 May; 68(84):23195-206. PubMed ID: 12725239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should the DEA conduct a "patient impact assessment" when promulgating new restrictions on controlled substance distribution?
    Brushwood DB
    J Pain Palliat Care Pharmacother; 2008; 22(4):322-6. PubMed ID: 21923319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clarification of registration requirements for individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2006 Dec; 71(231):69478-80. PubMed ID: 17171847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Schedules of controlled substances: placement of lacosamide into schedule V. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2009 May; 74(97):23789-90. PubMed ID: 19507328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Drug Enforcement Administration guideline for communicating controlled substance prescriptions to pharmacies.
    Drug Enforcement Adminstration U S Department of Justice
    J Pain Palliat Care Pharmacother; 2011; 25(1):83-9. PubMed ID: 21426229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Schedules of Controlled Substances: Removal of [123I]Ioflupane From Schedule II of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2015 Sep; 80(176):54715-8. PubMed ID: 26364325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The federal Drug Enforcement Administration "prescription series" proposal: continuing concerns.
    Gilson AM; Joranson DE
    J Pain Palliat Care Pharmacother; 2007; 21(4):21-4. PubMed ID: 18032312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Schedule of controlled substances: placement of dichloralphenazone into Schedule IV. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2001 Aug; 66(159):42943-4. PubMed ID: 11794309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.